Agilysys plans sale of 66,205 common shares

Agilysys, Inc. (AGYS) filed a notice of proposed sales of common stock.

Rhea-AI Filing Summary

Agilysys, Inc. (AGYS) filed a notice of proposed sales of common stock. The plan covers 66,205 common shares to be sold through Fidelity Brokerage Services LLC on or after August 5, 2026 on the NASDAQ market, with an indicated aggregate market value of $7,257,802.34. Shares outstanding are listed as 28,205,788, a baseline figure, not the amount being sold.

The shares derive from equity compensation: 11,309 shares from restricted stock vesting dated March 10, 2025, 49,926 shares from stock appreciation rights (SAR) dated May 28, 2024, and 4,970 shares from restricted stock vesting dated May 21, 2025, each identified as compensation granted by the issuer.

Key Figures

Shares to be sold: 66,205 shares Aggregate market value: $7,257,802.34 Shares outstanding: 28,205,788 shares +4 more

7 metrics

Shares to be sold 66,205 shares Common stock covered by the planned sale

Aggregate market value $7,257,802.34 Value associated with the 66,205 shares to be sold

Shares outstanding 28,205,788 shares Common shares outstanding referenced in the notice

Planned sale date 08/05/2026 Date tied to the proposed NASDAQ sale

Restricted stock vesting (03/10/2025) 11,309 shares Compensation shares identified for sale

SAR grant (05/28/2024) 49,926 shares Stock appreciation right shares identified for sale

Restricted stock vesting (05/21/2025) 4,970 shares Additional compensation shares identified for sale

Key Terms

Restricted Stock Vesting, SAR, Compensation

3 terms

Restricted Stock Vesting financial

"Common | 03/10/2025 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

SAR financial

"Common | 05/28/2024 | SAR | Issuer"

Compensation financial

"03/10/2025 | Restricted Stock Vesting | Issuer | | | 11309 | 03/10/2025 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What amount of Agilysys (AGYS) stock is covered by this planned sale?

The filing covers a proposed sale of 66,205 common shares of Agilysys stock. These shares come from equity compensation grants, including restricted stock vesting and stock appreciation rights, and are planned to be sold through Fidelity Brokerage Services LLC.

What is the aggregate market value of the Agilysys (AGYS) shares in this Form 144?

The aggregate market value of the 66,205 Agilysys shares covered is listed as $7,257,802.34. This value is tied to the planned sale amount and reflects the market valuation used in the notice of proposed sale.

When are the Agilysys (AGYS) shares expected to be sold and on which exchange?

The shares are planned to be sold on or after August 5, 2026 on the NASDAQ market. The notice lists NASDAQ as the trading venue and specifies this date in connection with the proposed transaction.

How were the Agilysys (AGYS) shares in this filing acquired?

The 66,205 shares were acquired through compensation from the issuer, including restricted stock vesting and stock appreciation rights (SAR). Specific acquisition dates include March 10, 2025, May 28, 2024, and May 21, 2025.

How many Agilysys (AGYS) shares are shown as outstanding in this notice?

The document lists 28,205,788 Agilysys common shares as outstanding. This figure provides context for the company’s total share base and is separate from the 66,205 shares covered by the proposed sale.

Who is the broker handling the proposed Agilysys (AGYS) share sale?

The proposed sale is designated to be handled by Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. This broker is identified in connection with the 66,205 common shares to be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:18 PM Accepted by SEC EDGAR 08/05/2026 - 04:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001277036
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AGILYSYS INC
SEC File Number	000-05734
Address of Issuer	3655 BROOKSIDE PARKWAY SUITE 300 ALPHARETTA GEORGIA 30022
Phone	7708107800
Name of Person for Whose Account the Securities are To Be Sold	SRINIVASAN RAMESH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	66205	7257802.34	28205788	08/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/10/2025	Restricted Stock Vesting	Issuer			11309	03/10/2025	Compensation
Common	05/28/2024	SAR	Issuer			49926	05/28/2024	Compensation
Common	05/21/2025	Restricted Stock Vesting	Issuer			4970	05/21/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ramesh Srinivasan.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)